Drug delivery through BBB

One of the biggest challenges in the drug discovery and development for CNS disorders is to achieve significant blood–brain barrier (BBB) penetration.

Many drugs do not have high lipid solubility, low molecular size and positive charge to traverse BBB. The issues associated with the blood–brain barrier are 1. The drug produced allows only a small portion to pass through the barrier 2. Binding to other proteins in the body makes the drug ineffective or pass through the barrier with that adhered protein. 3. The presence of enzymes in the brain that could render the drug inactive. All of these problems must be addressed to deliver effective drugs to the brain.

Developed strategies enhance the capacity of drug to cross the BBB by modifying the drug or by coupling it to a vector for receptor-mediated or adsorption-mediated transcytosis.

Compounds using BBB technology in the clinical development would reach approximately eight by 2019. The global market for BBB technologies was valued at $38.7 million in 2014. The market is expected to grow to $471.5 million by 2019, and register a tremendous 64.9% CAGR from 2014 through 2019.